http://www.businesswire.com Business Wire - The global leader in news distribution en Copyright 2010, Business Wire. WebSupport@BusinessWire.com WebSupport@BusinessWire.com Wed, 10 Feb 2010 13:21:41 UT Wed, 10 Feb 2010 13:21:41 UT http://www.businesswire.com http://www.businesswire.com Business Wire - The global leader in news distribution http://www.businesswire.com/images/bwlogo_small.gif 100 36 Mon, 8 Feb 2010 12:28:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive, engaging, easy-to-use, and low-cost way to manage their health & wellness, prevention and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100208005815&newsLang=en 20100208005815en Thu, 4 Feb 2010 21:00:00 UT MANCHESTER, England & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of the diagnostic agreement have not been disclosed. On April 16, 2008, Pfizer and Celldex The http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100204006544&newsLang=en 20100204006544en Wed, 3 Feb 2010 12:00:00 UT http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100203005875&newsLang=en 20100203005875en Wed, 27 Jan 2010 17:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development. “This pipeline of investigational medicines represents the strong future of Pfizer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100127006345&newsLang=en 20100127006345en Fri, 22 Jan 2010 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas. Sunitinib more than doubled the time patients with pancreatic neuroendocrine tumors lived without disease progression compared with patients treated with placebo, according to study findings that will be presented tomorrow at the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100122005360&newsLang=en 20100122005360en Thu, 21 Jan 2010 12:00:00 UT COLLEGEVILLE, Pa. & MALVERN, Pa.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that Pfizer received notification from the European Medicines Agency that the Marketing Authorization Application (MAA) for XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, biologic for the treatment of Dupuytren’s contracture (a condition resulting in the contracture of the fingers into the palm), has completed the vali http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100121005694&newsLang=en 20100121005694en Thu, 7 Jan 2010 13:00:00 UT LAUSANNE, Switzerland & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Under the terms of the agreement, Debiopharm will assume http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100107005952&newsLang=en 20100107005952en Wed, 6 Jan 2010 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) today announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ow http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100106006109&newsLang=en 20100106006109en Tue, 5 Jan 2010 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, PharmaTherapeutics Research & Development, at the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2010 at 8:30 a.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “28th Annual J.P. Morgan Healthcare Conference” link in the Investor Presen http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100105005648&newsLang=en 20100105005648en Mon, 4 Jan 2010 17:11:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Jeff Kindler, Chairman & CEO, at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Wednesday, January 6, 2010 at 8:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs Healthcare CEOs Unscripted: A View from the Top” link in the Investor Presentations tab on our homep http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100104005924&newsLang=en 20100104005924en Mon, 4 Jan 2010 17:10:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission has approved Revatio® (sildenafil) solution for injection for patients who are currently prescribed oral Revatio and who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable. Revatio is the only phosphodiesterase 5 (PDE5) inhibitor with both oral and I.V. formulations approved in the European Union for the treatment of PAH. Pulmonary arterial hypertension is http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20100104005921&newsLang=en 20100104005921en Wed, 30 Dec 2009 22:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine. As a result, the review will continue beyond the prescription drug user fee (PDUFA) action date of December 30, 2009. “We remain confident that the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091230005225&newsLang=en 20091230005225en Tue, 29 Dec 2009 22:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination. An analysis by an independent Data Safety Monitoring Committee (DSMC) showed that the addition of figitumumab to paclit http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091229005376&newsLang=en 20091229005376en Thu, 24 Dec 2009 00:06:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Food and Drug Administration (FDA) issued a Complete Response letter regarding the company’s New Drug Application (NDA) for Lyrica® (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD). The FDA determined that the data contained in the NDA were insufficient to support approval. The application was a resubmission in response to a “not-approvable” letter issued b http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091223005634&newsLang=en 20091223005634en Wed, 23 Dec 2009 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Wednesday, February 3, 2010. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2009 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091223005015&newsLang=en 20091223005015en Fri, 18 Dec 2009 18:13:00 UT MADISON, N.J.--(BUSINESS WIRE)--How will you achieve the “healthy” part of your New Year's resolutions? Your approach probably depends on whether you’re a woman or a man. According to a new national survey sponsored by Centrum® Ultra multivitamins, a line of scientifically-advanced, gender-and age-specific adult multivitamins, nearly all Americans (93 percent) surveyed have established at least one new health and wellness goal in the past year, but the survey shows that me http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091218005648&newsLang=en 20091218005648en Thu, 17 Dec 2009 23:03:00 UT RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). SPIRIVA HandiHaler is already FDA-approved as a once-daily maintenance treatment for breathing problems associated with COPD, which includes chronic http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091217006384&newsLang=en 20091217006384en Wed, 16 Dec 2009 22:01:00 UT NEW YORK--(BUSINESS WIRE)--Patients treated with Toviaz® (fesoterodine fumarate) 8 mg extended release tablets had greater and statistically significant reductions in urge urinary incontinence episodes at week 12 (P=0.017) compared with Detrol® LA (tolterodine tartrate extended release capsules) in a placebo-controlled randomized clinical trial. The primary endpoint of the study was reductions in urge urinary incontinence episodes. This new study, published today in the January issue o http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091216006218&newsLang=en 20091216006218en Tue, 15 Dec 2009 14:28:00 UT http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091215005758&newsLang=en 20091215005758en Mon, 14 Dec 2009 20:08:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent first-quarter 2010 dividend on the company’s common stock, payable March 2, 2010, to shareholders of record at the close of business on February 5, 2010. Pfizer increased the dividend by 12.5 percent, to 18 cents from 16 cents per share. “The board has determined that a measured dividend increase can be supported at this time,” said Jeffrey Kindler, Pfizer Chairman and Chief E http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091214006172&newsLang=en 20091214006172en Mon, 14 Dec 2009 19:34:00 UT NEW YORK--(BUSINESS WIRE)--Swine producers have a new conditionally-licensed vaccine from Pfizer Animal Health to help protect their herds from the pandemic H1N1 (pH1N1) strain of Swine Influenza Virus (SIV).1 Pfizer Animal Health today announced that its Swine Influenza Vaccine, pH1N1 – Killed Virus, has been approved by the U.S. Department of Agriculture (USDA) for vaccination of healthy swine, including pregnant sows and gilts, three weeks of age or older against SIV subtype H1N1. Pfize http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091214006130&newsLang=en 20091214006130en Sun, 13 Dec 2009 02:49:00 UT NEW YORK--(BUSINESS WIRE)--In connection with the New York Times’ recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper’s account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines. Premarin (conjugated estrogens tablets USP) and Prempro (conjugated estrogens/medroxyprogesterone acetate tablets), which are approved by the Food a http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091212005031&newsLang=en 20091212005031en Sat, 12 Dec 2009 23:30:00 UT SAN ANTONIO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Neratinib is now part of Pfizer’s expanded oncology portfolio, following the recent acquisition of Wyeth. “Data gathered from on http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091212005017&newsLang=en 20091212005017en Fri, 11 Dec 2009 10:52:00 UT NEW YORK--(BUSINESS WIRE)--The European Commission has granted Pfizer Inc. (NYSE: PFE) a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disea http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091211005205&newsLang=en 20091211005205en Thu, 10 Dec 2009 19:25:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the appointment of Adele Gulfo, U.S. President, Primary Care. In this new position, Ms. Gulfo is responsible for the company’s U.S. Primary Care business, including its five Regional Business Units, commercial operations, marketing, and corporate and government customer relationships. She reports to Olivier Brandicourt, President and General Manager of Pfizer’s Worldwide Primary Care business. “This is a pivotal http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091210005995&newsLang=en 20091210005995en Thu, 10 Dec 2009 18:41:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced it will extend its MAINTAIN™ (Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010. In addition to the more than 70 Pfizer primary care medicines currently available through MAINTAIN, Pfizer will extend the benefits of MAINTAIN to many legacy Wyeth medicines. Pfizer launched MAINTAIN in May to help unemployed and uninsured Americans stay on their Pfizer medicines. The p http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091210005259&newsLang=en 20091210005259en Thu, 10 Dec 2009 16:42:00 UT SAN ANTONIO--(BUSINESS WIRE)--Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse. These data showed that women who switched to Aromasin® (exemestane tablets) after 2.5 years of tamoxifen experienced a 19 percent http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091210005747&newsLang=en 20091210005747en Wed, 9 Dec 2009 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today results of a survey the company recently sponsored that shows physicians are more likely to report side effects through an electronic health records (EHR) system, as compared to traditional paper methods. Nearly 60 percent of physicians who responded to the survey also agreed that adverse event reporting through an EHR system would improve patient care. “Patient safety continues to be a top priority at Pfizer,” said Freda Lewis-Hall, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091209005467&newsLang=en 20091209005467en Wed, 9 Dec 2009 01:03:00 UT SANTA CLARA, Calif. & NEW YORK--(BUSINESS WIRE)--In the PFIZER DISCLOSURE NOTICE section, the date should read December 8, 2009 (sted December 4, 2009). The corrected release reads: PFIZER AND CROWN BIOSCIENCE ANNOUNCE A COLLABORATION TO RESEARCH AND DEVELOP NEW TREATMENTS FOR ASIAN CANCERS Pfizer (PFE) and Crown Bioscience, Inc. (Crown) announced today that they have entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091208006647&newsLang=en 20091208006647en Fri, 4 Dec 2009 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13. Presentations will highlight results from long-term follow-up of Aromasin® (exemestane tablets) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091204005133&newsLang=en 20091204005133en Tue, 1 Dec 2009 11:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher’s disease. Under the terms of the agreement, Pfizer will receive exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix will retain the exclusive commercial http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091201005670&newsLang=en 20091201005670en Fri, 20 Nov 2009 18:18:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder. Bipolar disorder, which affects approximately 5.7 milli http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091120005653&newsLang=en 20091120005653en Fri, 20 Nov 2009 13:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations. Revatio is indicated for the treatment of adult patients with pulmonary arterial hypertension (WHO Group I) to improve exercise ability and delay clinical worsening. The delay in clinica http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091120005270&newsLang=en 20091120005270en Thu, 19 Nov 2009 21:36:00 UT RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee voted 11 to 1 that clinical data included in a supplemental new drug application (sNDA) provide substantial and convincing evidence to support the claim that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) reduces exacerbations (worsening of symptoms) in patients with chronic obstructive pulmonary disease (COPD). The advisory committee also v http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091119006276&newsLang=en 20091119006276en Thu, 19 Nov 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health wants families to talk with one another about bringing the family dog along when they travel to their Thanksgiving-to-New Year’s celebrations. For most people, the holidays are a time of joy and celebration. But some people feel guilty or sad about leaving their dog behind because they consider their dog part of the family. “In addition, this year, many families are experiencing tough economic times,” said Amy Trettien, DVM, Veter http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091119005855&newsLang=en 20091119005855en Thu, 19 Nov 2009 00:09:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children. The Company http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091118006447&newsLang=en 20091118006447en Wed, 18 Nov 2009 13:30:00 UT NEW YORK & GENEVA--(BUSINESS WIRE)--Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be devel http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091118005590&newsLang=en 20091118005590en Wed, 18 Nov 2009 09:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. Approximately one in 500 people suffer from an inherited disorder, called Familial Hypercholesterolemia (FH), which causes high levels of LDL-cholesterol (“bad” cholesterol) and an incre http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091118005436&newsLang=en 20091118005436en Mon, 9 Nov 2009 17:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth. This global network brings together scientific strengths from both companies, continues efforts to increase research productivity, focuses disease-area research in single locations and more efficiently uses the company’s real estate. Pfizer will have five main research sites that will http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091109006047&newsLang=en 20091109006047en Wed, 4 Nov 2009 21:33:00 UT SAN DIEGO--(BUSINESS WIRE)--New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Che http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091104006460&newsLang=en 20091104006460en Tue, 3 Nov 2009 13:00:00 UT NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD). The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, the leading AD medication worldwide, on neuropsychiatric http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091103005429&newsLang=en 20091103005429en Fri, 30 Oct 2009 12:30:00 UT http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091030005395&newsLang=en 20091030005395en Thu, 29 Oct 2009 21:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced that its Board of Directors has approved giving shareholders an advisory vote on executive compensation. The vote will first occur at Pfizer’s Annual Meeting of Shareholders in 2010 and will take place on a biennial basis thereafter. “The Board’s action continues Pfizer’s long tradition of seeking and responding to shareholder input on compensation and other corporate governance topics,” said Matthew Lepor http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091029006512&newsLang=en 20091029006512en Thu, 22 Oct 2009 20:16:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 16-cent fourth-quarter 2009 dividend on the company’s common stock, payable December 1, 2009, to shareholders of record at the close of business on November 6, 2009. The fourth-quarter 2009 cash dividend will be the 284th consecutive quarterly dividend paid by Pfizer. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091022006503&newsLang=en 20091022006503en Tue, 20 Oct 2009 11:00:00 UT http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091020005838&newsLang=en 20091020005838en Mon, 19 Oct 2009 18:14:00 UT NEW YORK--(BUSINESS WIRE)--A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed. Pfizer Animal Health is now the world’s leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals. The acquisition of many of Fort Dodge’s U.S. products allows Pfizer Animal Health to greatly diversify its U.S. portfolio, as well as bro http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091019006355&newsLang=en 20091019006355en Sat, 17 Oct 2009 21:00:00 UT PHILADELPHIA--(BUSINESS WIRE)--Pfizer Inc announced today that 24-week data from two clinical studies of the oral JAK inhibitor, CP-690,550, confirmed statistically significant ACR20 response and DAS28 remission rates for several doses versus placebo when given alone or in combination with methotrexate for patients with active rheumatoid arthritis (RA). The findings, which were presented this week at the 2009 ACR/ARHP Annual Scientific Meeting in Philadelphia, represent the final analyses from t http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091017005015&newsLang=en 20091017005015en Fri, 16 Oct 2009 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced that it has commenced a consent solicitation to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary:     Aggregate Debt Security Principal Description CUSIP No. Amount   6.700% Notes due 2011 026609AM $1,497,580,000 6.700% Notes due 2011 026609AJ $2,420,000 5.250% Notes due 2013 983024AA $1,500,000,000 5.500% Notes due 2014 983024AE $1, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091016005382&newsLang=en 20091016005382en Fri, 16 Oct 2009 04:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in numerous growing therapeutic areas, a robust pipeline, premier scientific and manufacturing capabil http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091016005880&newsLang=en 20091016005880en Thu, 15 Oct 2009 15:49:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders. Under the terms of the transaction, each outstanding share of Wyeth common stock has been converted into the right to receive $33 in cash (without interest) and 0.985 of a share of Pfizer common stock. Effective as of t http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091015005867&newsLang=en 20091015005867en Wed, 14 Oct 2009 16:50:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Wyeth. In addition, Pfizer has received approval from the Canadian Competition Bureau for the pending acquisition. With the receipt of these clearances, Pfizer has now satisfied the regulatory approval requirements under the merger agre http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091014006096&newsLang=en 20091014006096en Wed, 14 Oct 2009 11:49:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement with two subsidiaries of Mylan Inc. relating to a generic version of Vfend® (voriconazole), an antifungal agent. The agreement is limited to the tablet form of Vfend and does not cover Pfizer’s Vfend products for intravenous use or oral suspension. Pursuant to the agreement, Mylan will have the right to market voriconazole tablets in the United States in the first quarter of 2011. Additional de http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091014005626&newsLang=en 20091014005626en Thu, 8 Oct 2009 20:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry® (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy. “Pfizer is pleased that the Committee has recognized the effectiveness and safety profile of maraviroc in patients who are starting HIV therapy,&# http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20091008006176&newsLang=en 20091008006176en Wed, 30 Sep 2009 08:25:00 UT http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090930005475&newsLang=en 20090930005475en Tue, 29 Sep 2009 12:54:00 UT http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090929005789&newsLang=en 20090929005789en Fri, 25 Sep 2009 12:40:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the election of Frances D. Fergusson, Ph.D. and John P. Mascotte to its Board of Directors. Dr. Fergusson and Mr. Mascotte, current members of the Board of Directors of Wyeth, will join the Pfizer Board upon the closing of Pfizer’s pending acquisition of Wyeth in accordance with the terms of the merger agreement. Dr. Fergusson is President Emeritus and professor of art at Vassar College, where she became the ninth president in 1986 and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090925005324&newsLang=en 20090925005324en Fri, 25 Sep 2009 02:13:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the other countries where it has rights. Pfize http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090924006229&newsLang=en 20090924006229en Thu, 24 Sep 2009 12:28:00 UT BERLIN--(BUSINESS WIRE)--Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy. Updated data from an expansion cohort of a Phase 1 study with PF-02341066 in NSCLC pa http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090924005452&newsLang=en 20090924005452en Wed, 23 Sep 2009 18:18:00 UT DEL MAR, Calif.--(BUSINESS WIRE)--In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition’s impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half of respondents (49 percent) were tre http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090923006133&newsLang=en 20090923006133en Wed, 23 Sep 2009 14:21:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has earned a score of 100 — the highest possible — in the 2010 Corporate Equality Index, which evaluates U.S.-based businesses on their treatment of lesbian, gay, bisexual and transgender (LGBT) employees, investors and consumers. The Corporate Equality Index — published annually by the Human Rights Campaign Foundation (HRCF), the largest LGBT advocacy organization in the United States — rates businesses using http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090923005804&newsLang=en 20090923005804en Wed, 23 Sep 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has earned a score of 100 — the highest possible — in the 2010 Corporate Equality Index, which evaluates U.S.-based businesses on their treatment of lesbian, gay, bisexual and transgender (LGBT) employees, investors and consumers. The Corporate Equality Index — published annually by the Human Rights Campaign Foundation (HRCF), the largest LGBT advocacy organization in the United States — rates businesses using http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090923005774&newsLang=en 20090923005774en Tue, 22 Sep 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc has been named among the 2009 Working Mother 100 Best Companies for its steadfast commitment to family-friendly benefits. Pfizer and the other winning companies are pioneering programs that support families, with 100 percent offering flextime, on-site lactation and telecommuting; and 98 percent offering job-sharing and wellness programs—numbers that dwarf those seen nationwide. In addition, financial programs available to the 100 Best employees are on http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090922005906&newsLang=en 20090922005906en Tue, 22 Sep 2009 11:00:00 UT BERLIN--(BUSINESS WIRE)--Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events (HR=0.82; 95% CI: 0.73-0.92; P=0.0009), compared to women who continued on tamoxifen for a full five years of treatment.1 In addition, IES showed that AROMASIN prolonged over http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090922005718&newsLang=en 20090922005718en Mon, 21 Sep 2009 21:05:00 UT NEW YORK & MADISON, N.J.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer’s pending acquisition of Wyeth. Under the terms of the agreement, Boehringer Ingelheim will acquire products, research and manufacturing facilities, located in Fort Dodge, Iowa, as well as related assets and in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090921006526&newsLang=en 20090921006526en Mon, 21 Sep 2009 18:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc has been commended by the Carbon Disclosure Project (CDP) for its approach to addressing climate change. CDP named Pfizer to its Climate Disclosure Leadership Index, which highlights the company’s climate change disclosure practices. This is the third consecutive year that Pfizer has been recognized by CDP. “As a health care company, Pfizer is very aware of the potential impact of climate change on global health,” said Steve Brooks, vice pr http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090921006303&newsLang=en 20090921006303en Fri, 18 Sep 2009 17:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET),2 and early-stage research of investigational agents PF-023410663 and figitumumab (CP-751,871)4 in patients with non-small cell lung cancer (NSCLC). These data, and over a do http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090918005746&newsLang=en 20090918005746en Wed, 9 Sep 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 20, 2009. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2009 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090909005138&newsLang=en 20090909005138en Tue, 8 Sep 2009 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Established Products, and Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2009 at 8:35 a.m. Eastern Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global He http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090908006061&newsLang=en 20090908006061en Wed, 2 Sep 2009 14:29:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005. The final agreement also resolves other DOJ investigations involving alleged past off-label promotional practices concerning Zyvox, Geodon and Lyrica, allegations related to certain pay http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090902005690&newsLang=en 20090902005690en Tue, 1 Sep 2009 15:17:00 UT DENVER--(BUSINESS WIRE)--Private practice isn’t for everyone, but for graduating veterinary students facing an average of $120,000 in debt, it often is the only logical choice. A new program—the Pfizer Animal Health–Morris Animal Foundation (MAF) Veterinary Fellowship for Advanced Study—gives current practitioners necessary financial support while they pursue a veterinary research career. The program commits a minimum of nearly $1.7 million over four years toward a soluti http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090901006134&newsLang=en 20090901006134en Tue, 1 Sep 2009 06:30:00 UT BARCELONA, Spain--(BUSINESS WIRE)--For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain. By contrast, traditional lipid risk factors were strong predictors of cardiovascular events. The findings are based on a new post h http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090831005855&newsLang=en 20090831005855en Wed, 26 Aug 2009 14:30:00 UT WASHINGTON--(BUSINESS WIRE)--The Corporate Council on Africa (CCA) announced today that Pfizer Inc will sponsor the 7th Biennial U.S. – Africa Business Summit: Realizing the Investment Power of Africa, to be held at the Walter E. Washington Convention Center in Washington, D.C., September 29 – October 1, 2009. At a Pfizer-sponsored workshop titled Mobilizing Resources for Strengthening African Health Systems: A Case Study of Pfizer’s Global Health Fellows, Charles Shafran, form http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090826005527&newsLang=en 20090826005527en Wed, 19 Aug 2009 16:48:00 UT NEW YORK--(BUSINESS WIRE)--Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090819005806&newsLang=en 20090819005806en Thu, 6 Aug 2009 16:30:00 UT NEW YORK--(BUSINESS WIRE)--President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090806005853&newsLang=en 20090806005853en Thu, 30 Jul 2009 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced it has reached agreement with the Kano State government in Nigeria to settle Kano State’s claims arising from the 1996 Trovan clinical study, which was http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090730005769&newsLang=en 20090730005769en Thu, 30 Jul 2009 12:30:00 UT NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine)* in patients http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090730005524&newsLang=en 20090730005524en Wed, 29 Jul 2009 15:00:00 UT SHANGHAI, China--(BUSINESS WIRE)--Pfizer today announced a partnership with Fudan University to establish a graduate program in Clinical Data Management and Statistical Programming. This three year Masters Degree http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090729005783&newsLang=en 20090729005783en Wed, 29 Jul 2009 14:00:00 UT SHANGHAI, China--(BUSINESS WIRE)--Pfizer today announced a joint initiative with the Shanghai Institutes for Biological Sciences (SIBS) to support fundamental research in China. As part of the initiative, Pfizer China http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090729005723&newsLang=en 20090729005723en Wed, 29 Jul 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the BMO Capital Markets 9th Annual Focus On http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090729005753&newsLang=en 20090729005753en Wed, 22 Jul 2009 11:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090722005480&newsLang=en 20090722005480en Tue, 21 Jul 2009 09:30:00 UT NEW YORK--(BUSINESS WIRE)--At 96-week follow up, data from the MERIT ES analysis show that treatment-naïve HIV patients taking Celsentri/Selzentry (maraviroc), in combination with Combivir® http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090721005286&newsLang=en 20090721005286en Fri, 17 Jul 2009 17:46:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company’s pending acquisition of Wyeth. The http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090717005661&newsLang=en 20090717005661en Wed, 15 Jul 2009 13:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090715005684&newsLang=en 20090715005684en Thu, 9 Jul 2009 17:49:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it is disappointed by the Canadian Federal Court’s decision declaring invalid its patent covering amlodipine besylate, the active ingredient in Norvasc®, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090709005916&newsLang=en 20090709005916en Wed, 1 Jul 2009 21:08:00 UT NEW YORK--(BUSINESS WIRE)--Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Acquisition and License Agreement by http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090701006264&newsLang=en 20090701006264en Wed, 1 Jul 2009 16:49:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites media and investors to listen to a teleconference related to CHANTIX at 1:15 PM US/EST on Wednesday, July 1. In addition to providing an update on CHANTIX, Pfizer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090701005976&newsLang=en 20090701005976en Wed, 1 Jul 2009 16:16:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it has updated the U.S. product labeling for CHANTIX® (varenicline), a prescription aid to smoking cessation treatment, to communicate important safety http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090701005920&newsLang=en 20090701005920en Wed, 1 Jul 2009 15:30:00 UT --(BUSINESS WIRE)--Pfizer: WHAT:   An assistance program offered by Pfizer that can help unemployed Americans continue receiving their prescription medicines. The program is fully operational today, July 1. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090701005781&newsLang=en 20090701005781en Tue, 30 Jun 2009 21:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090630006315&newsLang=en 20090630006315en Thu, 25 Jun 2009 17:50:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 16-cent third-quarter 2009 dividend on the company’s common stock, payable September 2, 2009, to shareholders of record http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090625005916&newsLang=en 20090625005916en Thu, 25 Jun 2009 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090625005278&newsLang=en 20090625005278en Thu, 18 Jun 2009 15:31:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 11 a.m. EDT on Wednesday, July 22, 2009. The purpose of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090618005667&newsLang=en 20090618005667en Thu, 18 Jun 2009 13:03:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective Pfizer’s Registration Statement on Form S-4. The Form S-4 registers with the SEC http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090618005453&newsLang=en 20090618005453en Thu, 11 Jun 2009 12:10:00 UT COPENHAGEN--(BUSINESS WIRE)--Pfizer announced today that data from two new mid-stage clinical studies of the company’s oral JAK-3 inhibitor, CP-690,550, showed statistically significant response versus placebo http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090611005385&newsLang=en 20090611005385en Wed, 3 Jun 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Established Products, at the Goldman Sachs 30th http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090603005228&newsLang=en 20090603005228en Wed, 3 Jun 2009 13:36:00 UT MONTREAL--(BUSINESS WIRE)--Pfizer Animal Health today announced that the U.S. Food and Drug Administration (FDA) has approved the first canine cancer therapy in the U.S. – PALLADIATM (toceranib phosphate) – http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090603005692&newsLang=en 20090603005692en Wed, 3 Jun 2009 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the successful completion of its offering of €5.85 billion and £1.50 billion of senior unsecured notes (totaling approximately $10.5 billion). The notes http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090603005612&newsLang=en 20090603005612en Tue, 2 Jun 2009 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Toviaz™ (fesoterodine fumarate) extended release tablets and the YourWay™ plan (www.ToviazYourWay.com), a comprehensive, customizable support plan http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090602005601&newsLang=en 20090602005601en Mon, 1 Jun 2009 21:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090601006401&newsLang=en 20090601006401en Sat, 30 May 2009 16:01:00 UT ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today results from studies evaluating the company’s investigational anti-insulin growth factor- type 1 receptor (IGF-1R) antibody, figitumumab (CP-751,871), in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090530005024&newsLang=en 20090530005024en Sat, 30 May 2009 12:24:00 UT ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today results from four studies highlighting clinical data with targeted treatment approaches in patients with non-small cell lung cancer (NSCLC). Data on the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090530005019&newsLang=en 20090530005019en Fri, 29 May 2009 16:13:00 UT ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today, at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting, the results of several clinical studies that may help identify patients who are more http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090529005511&newsLang=en 20090529005511en Fri, 29 May 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors, media and the general public to view and listen to a webcast of a conference call with investment analysts at 1:00 p.m. EDT on Friday, June 12, 2009. The purpose http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090529005276&newsLang=en 20090529005276en Thu, 28 May 2009 00:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal document (FAD) recommending reimbursement for http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090527006444&newsLang=en 20090527006444en Wed, 20 May 2009 12:39:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has entered into licensing agreements with two pharmaceutical companies based in India, strengthening its position in emerging markets and significantly http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090520005604&newsLang=en 20090520005604en Tue, 19 May 2009 19:00:00 UT SAN FRANCISCO--(BUSINESS WIRE)--The addition of Pfizer’s Lyrica® (pregabalin) capsules CV to other generalized anxiety disorder (GAD) treatments significantly improved the symptoms of the condition in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090519006509&newsLang=en 20090519006509en Tue, 19 May 2009 14:54:00 UT PARIS--(BUSINESS WIRE)--Pfizer Animal Health today announced that The European Commission has given Pfizer the go-ahead to market its innovative swine vaccine, Improvac®, across the European Union (EU). http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090519006091&newsLang=en 20090519006091en Thu, 14 May 2009 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it will launch an innovative program to help eligible unemployed Americans and their families who have lost their health insurance maintain access to their http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090514005582&newsLang=en 20090514005582en Wed, 13 May 2009 16:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer will present new data highlighting the company’s commitment to a personalized approach to oncology clinical research, which includes the use of targeted agents in specific http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090513005980&newsLang=en 20090513005980en Tue, 12 May 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Frank D’Amelio, Chief Financial Officer, at the 34th Annual Deutsche Bank http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090512005159&newsLang=en 20090512005159en Tue, 12 May 2009 13:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Greg Simon has joined the company as Senior Vice President, Worldwide Policy. He comes to Pfizer from the presidency of FasterCures, where he led efforts to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090513006350&newsLang=en 20090513006350en Tue, 5 May 2009 18:32:00 UT MADISON, Wis.--(BUSINESS WIRE)--Pfizer, Inc (NYSE: PFE), the world's premier biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, non-profit patenting and licensing organization http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090505006451&newsLang=en 20090505006451en Mon, 4 May 2009 20:16:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Freda Lewis-Hall, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Pfizer Inc. Dr. Lewis-Hall will be the senior physician in the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090504006250&newsLang=en 20090504006250en Wed, 29 Apr 2009 19:30:00 UT SEATTLE--(BUSINESS WIRE)--Patients suffering from post-traumatic peripheral nerve pain treated with Lyrica® (pregabalin) capsules CV experienced significantly reduced pain compared to those taking placebo, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090429006303&newsLang=en 20090429006303en Wed, 29 Apr 2009 15:15:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Bernstein http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090429005752&newsLang=en 20090429005752en Tue, 28 Apr 2009 11:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090428005625&newsLang=en 20090428005625en Fri, 24 Apr 2009 12:30:00 UT NEW YORK--(BUSINESS WIRE)--According to the World Health Organization (WHO) malaria infects approximately 250 million people per year throughout the developing world and results in a grave loss of life of at least http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090424005334&newsLang=en 20090424005334en Fri, 24 Apr 2009 07:00:00 UT CAMBRIDGE, England--(BUSINESS WIRE)--Pfizer Regenerative Medicine today announced that it has entered into a collaboration and license agreement with University College London focused on gaining better understanding http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090424005082&newsLang=en 20090424005082en Thu, 23 Apr 2009 14:36:00 UT ATLANTA--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 16-cent second-quarter 2009 dividend on the company’s common stock, payable June 2, 2009, to shareholders of record at the close of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090423005779&newsLang=en 20090423005779en Wed, 22 Apr 2009 15:00:00 UT NEW YORK & GENEVA--(BUSINESS WIRE)--Pfizer Inc and Medicines for Malaria Venture (MVV) have signed an agreement that is designed to facilitate advancements in the battle against malaria, a disease that afflicts http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090422006055&newsLang=en 20090422006055en Wed, 22 Apr 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Newly released findings from the BRIDGE survey (Bridging Gaps, Expanding Outreach – Metastatic Breast Cancer Patient Survey) found that most (78 percent) women living with metastatic http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090422005738&newsLang=en 20090422005738en Mon, 20 Apr 2009 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 23. To access the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090420005983&newsLang=en 20090420005983en Mon, 13 Apr 2009 02:00:00 UT MUMBAI, India--(BUSINESS WIRE)--Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, announced today that it will make a tender offer to acquire a 33.77% stake in Pfizer Limited from http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090412005013&newsLang=en 20090412005013en Fri, 10 Apr 2009 13:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the appointment of Martine J. George, M.D., M.Sc, to Vice President of Medical Affairs for its Oncology Business Unit. Dr. George will be responsible for managing http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090410005091&newsLang=en 20090410005091en Tue, 7 Apr 2009 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) today announced the planned leadership and organizational structure for its research and commercial operations that will become effective when the Wyeth acquisition closes. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090407006027&newsLang=en 20090407006027en Fri, 3 Apr 2009 18:23:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) today announced that it has received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to its previously http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090403005625&newsLang=en 20090403005625en Fri, 3 Apr 2009 16:32:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has become the first pharmaceutical company to be accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090403005547&newsLang=en 20090403005547en Thu, 2 Apr 2009 16:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today provided an update to its pipeline, highlighting the progression of clinical programs in high-priority therapeutic areas, and announced the start of Phase 3 clinical trials http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090402005903&newsLang=en 20090402005903en Thu, 2 Apr 2009 12:29:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the discontinuation of one of its Phase 3 studies based on statistical assessment for futility: the SUN 1107 Phase 3 study of Sutent® (sunitinib malate) in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090402005273&newsLang=en 20090402005273en Tue, 31 Mar 2009 13:00:00 UT ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer Inc today announced the results of a study that found that 47 percent of smokers with a history of cardiovascular disease who took CHANTIX/CHAMPIX® (varenicline) were able to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090331005954&newsLang=en 20090331005954en Mon, 30 Mar 2009 19:30:00 UT NEW YORK--(BUSINESS WIRE)--Among patients aged 65 and older with established coronary heart disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the relative risk of a first cardiovascular event by http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090330006302&newsLang=en 20090330006302en Mon, 30 Mar 2009 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2009. The purpose of the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090330005696&newsLang=en 20090330005696en Wed, 25 Mar 2009 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced the successful completion of its offering of $13.5 billion of senior unsecured notes. The notes consist of: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090325005498&newsLang=en 20090325005498en Mon, 23 Mar 2009 14:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the appointment of Elizabeth Barrett to Regional President, U.S. for its Oncology Business Unit where she will lead sales, field operations, and marketing. Ms. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090323005787&newsLang=en 20090323005787en Fri, 20 Mar 2009 09:00:00 UT NEW YORK & PARIS--(BUSINESS WIRE)--Pfizer Inc and PlaNet Finance announced today that they will team up to conduct an in-depth research project on the healthcare needs of the working poor in China. The study will http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090320005156&newsLang=en 20090320005156en Thu, 19 Mar 2009 11:10:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Together Rx Access®, a prescription savings program sponsored by Pfizer along with several other leading pharmaceutical companies, has expanded the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090319005413&newsLang=en 20090319005413en Tue, 17 Mar 2009 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has granted reissue patent RE40667, relating to Lipitor. The company had applied for the reissue patent in January 2007, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090317005681&newsLang=en 20090317005681en Fri, 13 Mar 2009 07:00:00 UT NEW YORK--(BUSINESS WIRE)--A new global survey of 950 women living with metastatic breast cancer (MBC) in nine countries (the United Kingdom, France, Spain, Belgium, Poland, the United States, Argentina, Egypt and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090313005169&newsLang=en 20090313005169en Tue, 10 Mar 2009 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a discussion with members of Pfizer’s leadership team at an investor breakfast at the Cowen and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090310005445&newsLang=en 20090310005445en Tue, 3 Mar 2009 13:25:00 UT NEW YORK & ROCHESTER, N.Y.--(BUSINESS WIRE)--Pfizer Inc and Bausch & Lomb announced today a co-promotion agreement involving both companies’ prescription ophthalmic pharmaceuticals in the United States. The http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090303005745&newsLang=en 20090303005745en Tue, 3 Mar 2009 08:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today that it has entered into a series of agreements with Aurobindo Pharma Ltd., a pharmaceutical company based in India, to commercialize medicines that are http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090303006377&newsLang=en 20090303006377en Tue, 24 Feb 2009 13:32:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that, following a review of the development and commercial portfolios in the Primary Care Business Unit, it is terminating Phase 3 development programs for the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090224005766&newsLang=en 20090224005766en Mon, 9 Feb 2009 21:15:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced its plans to make publicly available its compensation of U.S. healthcare professionals for consulting, speaking engagements and clinical trials. The disclosure will http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090209006347&newsLang=en 20090209006347en Wed, 4 Feb 2009 17:08:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc and The Pfizer Foundation announced today, on “World Cancer Day”, that they have awarded $7 million in 2009 to help 13 non-governmental organizations (NGOs) focus on http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090204005961&newsLang=en 20090204005961en Wed, 4 Feb 2009 00:29:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal document (FAD) recommending the use of Sutent http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090203006803&newsLang=en 20090203006803en Mon, 2 Feb 2009 13:30:00 UT NEW YORK--(BUSINESS WIRE)--Patients treated with Lipitor® (atorvastatin calcium) 80 mg had a significant 55 percent reduction in levels of high-sensitivity C-reactive protein (hsCRP), while those taking Lipitor 10 http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090202005686&newsLang=en 20090202005686en Fri, 30 Jan 2009 22:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090130005733&newsLang=en 20090130005733en Tue, 27 Jan 2009 16:35:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to an audio-only webcast of a discussion with the Pfizer leadership team at an investor luncheon on Tuesday, January 27, 2009 at http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090127006056&newsLang=en 20090127006056en Mon, 26 Jan 2009 11:35:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they will be holding a live press conference to discuss today’s announcement that Pfizer will acquire Wyeth. The executives http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090126005631&newsLang=en 20090126005631en Mon, 26 Jan 2009 11:29:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090126005627&newsLang=en 20090126005627en Mon, 26 Jan 2009 11:27:00 UT NEW YORK & MADISON, N.J.--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090126005624&newsLang=en 20090126005624en Fri, 16 Jan 2009 22:05:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today it has received a complete response letter from the U.S. Food and Drug Administration (FDA) asking for additional information on the company’s application for http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090116005785&newsLang=en 20090116005785en Wed, 14 Jan 2009 13:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the election of Stephen W. Sanger to its Board of Directors, effective February 1, 2009. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090114005649&newsLang=en 20090114005649en Tue, 6 Jan 2009 18:06:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” accepting the company’s application to correct the technical defect http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20090106006198&newsLang=en 20090106006198en Mon, 22 Dec 2008 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & Development, at the 27th Annual http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081222005230&newsLang=en 20081222005230en Mon, 22 Dec 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that Bradley E. Lerman will join the company as Senior Vice President, Litigation. Mr. Lerman, who will be responsible for leading the company’s http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081222005369&newsLang=en 20081222005369en Mon, 15 Dec 2008 20:45:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 32-cent first-quarter 2009 dividend on the company’s common stock, payable March 3, 2009, to shareholders of record at http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081216005690&newsLang=en 20081216005690en Mon, 15 Dec 2008 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Wednesday, January 28, 2009. The purpose of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081215005798&newsLang=en 20081215005798en Thu, 11 Dec 2008 20:00:00 UT SAN ANTONIO--(BUSINESS WIRE)--Pfizer today announced results from a first planned analysis of the TEAM (Tamoxifen, Exemestane, Adjuvant, Multicenter) trial. TEAM was originally designed in 2001 as a comparison of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081211006034&newsLang=en 20081211006034en Tue, 9 Dec 2008 13:30:00 UT NEW YORK & ROME, Italy--(BUSINESS WIRE)--Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, announced today that they have entered http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081209005784&newsLang=en 20081209005784en Wed, 3 Dec 2008 13:18:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced the results of an observational study that showed patients taking Lipitor® (atorvastatin calcium) had a significant 13 percent reduction in the relative risk of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081203005577&newsLang=en 20081203005577en Tue, 25 Nov 2008 22:45:00 UT NEW YORK--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted SELZENTRY™ (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081125006144&newsLang=en 20081125006144en Thu, 20 Nov 2008 10:28:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has withdrawn its application to switch the legal status of the 50 mg tablet strength of Viagra from ‘prescription only’ to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081120005432&newsLang=en 20081120005432en Fri, 14 Nov 2008 11:00:00 UT LONDON--(BUSINESS WIRE)--Pfizer today announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081114005161&newsLang=en 20081114005161en Fri, 14 Nov 2008 11:00:00 UT LONDON--(BUSINESS WIRE)--Pfizer today announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081114005281&newsLang=en 20081114005281en Wed, 12 Nov 2008 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Improvements in kidney function in patients treated with Lipitor® (atorvastatin calcium) were shown to strongly http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081112005856&newsLang=en 20081112005856en Thu, 6 Nov 2008 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Jeff Kindler, Chairman and CEO, at the 2008 Credit Suisse http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081106005124&newsLang=en 20081106005124en Wed, 5 Nov 2008 21:35:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer, Inc announced today that it is terminating the phase 3 development program for its investigational compound (CP-945,598) for weight management. CP-945,598 http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081105006339&newsLang=en 20081105006339en Fri, 31 Oct 2008 17:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) approved TOVIAZ™ (fesoterodine http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081031005701&newsLang=en 20081031005701en Sun, 26 Oct 2008 15:16:00 UT NEW YORK--(BUSINESS WIRE)--Patients taking Selzentry, in combination with Combivir® (zidovudine/lamivudine) and selected by an enhanced sensitivity tropism http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081026005059&newsLang=en 20081026005059en Sun, 26 Oct 2008 00:00:00 UT SAN FRANCISCO--(BUSINESS WIRE)--Pfizer will present data on three investigational compounds that represent potential new mechanisms for targeting pain and inflammation. These data will http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081025005025&newsLang=en 20081025005025en Thu, 23 Oct 2008 17:40:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 32-cent fourth-quarter 2008 dividend on the company’s common http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081023006120&newsLang=en 20081023006120en Wed, 22 Oct 2008 16:46:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has finalized agreements with 33 states and the District of Columbia to resolve claims primarily related to alleged promotional http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081022006046&newsLang=en 20081022006046en Wed, 22 Oct 2008 11:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has named Mace L. Rothenberg, M.D. as Senior Vice President, Clinical Development and Medical Affairs for its Oncology Business http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081022005517&newsLang=en 20081022005517en Tue, 21 Oct 2008 11:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081021005751&newsLang=en 20081021005751en Mon, 20 Oct 2008 12:00:00 UT LONDON--(BUSINESS WIRE)--Pfizer Ltd (NYSE:PFE) (LSE:PFZ) and UCB today announced the formation of Cyclofluidic, a breakthrough technology company established with the aim of significantly http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081020005677&newsLang=en 20081020005677en Fri, 17 Oct 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081017005371&newsLang=en 20081017005371en Tue, 14 Oct 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer will highlight several presentations and posters across a spectrum of pain and inflammatory conditions at the American College of Rheumatology (ACR) annual http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081015006403&newsLang=en 20081015006403en Thu, 9 Oct 2008 18:21:00 UT RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--Results of the UPLIFT® (Understanding Potential Long-term Impacts on Function with Tiotropium) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081015006425&newsLang=en 20081015006425en Thu, 9 Oct 2008 15:33:00 UT HARTFORD, Conn.--(BUSINESS WIRE)--Aetna and Pfizer Inc are co-sponsoring a recreational health fair for Hartford families on October 18 to raise awareness of the importance of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081009005649&newsLang=en 20081009005649en Wed, 8 Oct 2008 17:00:00 UT NEW YORK--(BUSINESS WIRE)--The U.S. Environmental Protection Agency (EPA) honored Pfizer Inc today in recognition of the company’s award-winning Energy and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081008005926&newsLang=en 20081008005926en Fri, 3 Oct 2008 20:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors, media and the general public to view and listen to a webcast of a presentation by Pfizer’s pain and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081003005688&newsLang=en 20081003005688en Wed, 1 Oct 2008 14:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081001005887&newsLang=en 20081001005887en Tue, 30 Sep 2008 13:34:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company’s http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080930005819&newsLang=en 20080930005819en Wed, 24 Sep 2008 16:08:00 UT INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and Pfizer have released a new analysis of 30 rigorously controlled clinical trials confirming the long term safety profile of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20081015006423&newsLang=en 20081015006423en Wed, 24 Sep 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc and Grameen Health, an affiliate of Grameen Bank, the pioneering micro-financing organization in Bangladesh that shared the Nobel Peace Prize in 2006 http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080924005579&newsLang=en 20080924005579en Mon, 22 Sep 2008 14:56:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that for the second consecutive year it was recognized for its approach to improving the environment by being named to the Climate http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080922006037&newsLang=en 20080922006037en Tue, 16 Sep 2008 12:06:00 UT VALENCIA, Calif. & NEW YORK--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) and Pfizer Inc (NYSE: PFE) announced today that MannKind will transition certain Exubera patients with a http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080916005881&newsLang=en 20080916005881en Mon, 15 Sep 2008 16:21:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the launch of a new interactive online educational resource designed to give healthcare professionals, medical students, patients, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080915006277&newsLang=en 20080915006277en Mon, 15 Sep 2008 12:56:00 UT STOCKHOLM, Sweden--(BUSINESS WIRE)--Pfizer announced today updated safety and efficacy results surrounding its investigational compound, CP-751,871, in patients with non-small cell lung http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080915005912&newsLang=en 20080915005912en Wed, 10 Sep 2008 22:27:00 UT PARIS--(BUSINESS WIRE)--Pfizer Animal Health today announced that its acquisition of multiple product franchises in Europe from the Schering-Plough Corporation has been completed and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080910006435&newsLang=en 20080910006435en Tue, 9 Sep 2008 12:32:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080909005943&newsLang=en 20080909005943en Mon, 8 Sep 2008 20:11:00 UT STOCKHOLM, Sweden--(BUSINESS WIRE)--Pfizer announced today that important study results involving the company’s leading anticancer agent, SUTENT http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080908006433&newsLang=en 20080908006433en Mon, 8 Sep 2008 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, President, Worldwide Pharmaceutical Operations, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080908005503&newsLang=en 20080908005503en Wed, 3 Sep 2008 11:00:00 UT NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080903005453&newsLang=en 20080903005453en Tue, 2 Sep 2008 12:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced that in patients with established heart disease, Lipitor® (atorvastatin calcium) 80 mg not only http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080902005492&newsLang=en 20080902005492en Tue, 2 Sep 2008 09:00:00 UT PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) announced today the results of a Phase 2 dose-ranging study (APPRAISE-1) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080902005425&newsLang=en 20080902005425en Fri, 29 Aug 2008 13:15:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company’s favor in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080829005287&newsLang=en 20080829005287en Tue, 26 Aug 2008 20:15:00 UT PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080826006372&newsLang=en 20080826006372en Thu, 14 Aug 2008 15:09:00 UT NEW YORK--(BUSINESS WIRE)--With canine motion sickness the leading reason pet owners are not able to take their dogs on day trips or vacation, Pfizer is encouraging more people to talk with http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080814005669&newsLang=en 20080814005669en Mon, 11 Aug 2008 15:03:00 UT LAS VEGAS--(BUSINESS WIRE)--The International Association of Fire Fighters has announced the launch of a new initiative to help fire fighters, family members and friends to quit smoking http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080811005842&newsLang=en 20080811005842en Wed, 6 Aug 2008 18:43:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080806006106&newsLang=en 20080806006106en Wed, 23 Jul 2008 11:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080723005527&newsLang=en 20080723005527en Mon, 14 Jul 2008 17:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer’s disease (AD) research and development program, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080714005974&newsLang=en 20080714005974en Thu, 10 Jul 2008 16:28:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer endorses the updates to the PhRMA Code on Interactions with Healthcare Professionals and will fully comply with all aspects of the Code. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080710005783&newsLang=en 20080710005783en Mon, 7 Jul 2008 16:20:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that new statin users who took Lipitor® (atorvastatin calcium) were significantly more http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080707005736&newsLang=en 20080707005736en Wed, 2 Jul 2008 16:09:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced changes in the way it supports continuing medical education (CME) initiatives for U.S. healthcare professionals. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080702005744&newsLang=en 20080702005744en Mon, 30 Jun 2008 12:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health has announced the Food and Drug Administration (FDA) has approved Convenia® (cefovecin sodium), the first and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080630005686&newsLang=en 20080630005686en Thu, 26 Jun 2008 16:00:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent third–quarter, 2008, dividend on the company http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080626005767&newsLang=en 20080626005767en Wed, 25 Jun 2008 16:04:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 11 a.m. Eastern Daylight http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080625005910&newsLang=en 20080625005910en Mon, 23 Jun 2008 16:55:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors, media, and the general public to view and listen to a webcast of a presentation by Pfizer’s http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080623005995&newsLang=en 20080623005995en Mon, 23 Jun 2008 13:00:00 UT SAN DIEGO--(BUSINESS WIRE)--EyeCyte, Inc., an early stage stem/progenitor cell-based ophthalmology research and development company based in La Jolla, California, today announced that it has http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080623005677&newsLang=en 20080623005677en Wed, 18 Jun 2008 11:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd. of India and certain of its affiliates to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080618005386&newsLang=en 20080618005386en Thu, 12 Jun 2008 15:49:00 UT NEW YORK--(BUSINESS WIRE)--This summer, Maria Machado, a supply chain expert from Brazil, will make an extended visit to Africa – unlike any trip she http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080612005831&newsLang=en 20080612005831en Thu, 12 Jun 2008 15:32:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has entered into a $15-million dollar collaboration with the University of Pennsylvania School of Medicine. The http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080612005800&newsLang=en 20080612005800en Tue, 10 Jun 2008 20:00:00 UT PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced today the start of a new Phase 3 clinical trial to assess the effect of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080610006500&newsLang=en 20080610006500en Tue, 10 Jun 2008 14:06:00 UT NEW YORK--(BUSINESS WIRE)--In a novel experiment to advance new drug discovery and development, as well as stimulate basic research, Pfizer, Inc. and UCSF have launched a collaboration that http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080610006037&newsLang=en 20080610006037en Tue, 10 Jun 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that it has completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals Inc. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080610005826&newsLang=en 20080610005826en Thu, 5 Jun 2008 20:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that Charles E. Triano will join the company as Senior Vice President, Investor Relations, effective June 23. Mr. Triano, who will be http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080605005850&newsLang=en 20080605005850en Wed, 4 Jun 2008 16:40:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080604005979&newsLang=en 20080604005979en Mon, 2 Jun 2008 23:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today as part of its commitment to oncology that it expects to start a total of seven Phase 3 studies in 2008; two are open and enrolling, and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080602006600&newsLang=en 20080602006600en Mon, 2 Jun 2008 20:02:00 UT CHICAGO--(BUSINESS WIRE)--Pfizer announced today results from several clinical trials further describing the activity of its investigational compound CP-751,871 in non-small cell lung cancer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080602006421&newsLang=en 20080602006421en Mon, 2 Jun 2008 15:34:00 UT CHICAGO--(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN) and Pfizer, Inc. (NYSE: PFE) today announced the presentation of new data from two Phase 2 studies at the 44th Annual http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080602006044&newsLang=en 20080602006044en Fri, 30 May 2008 16:14:00 UT --(BUSINESS WIRE)-- http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080530005552&newsLang=en 20080530005552en Wed, 28 May 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named Amy W. Schulman as Senior Vice President and General Counsel, effective June 23. In her new role, Ms. Schulman will be responsible for http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080528005671&newsLang=en 20080528005671en Wed, 28 May 2008 00:21:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Australian Full Federal Court in Victoria has upheld on appeal the exclusivity of its basic patent covering atorvastatin, the active http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080527006470&newsLang=en 20080527006470en Thu, 22 May 2008 13:52:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts and institutional investors to be held on http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080522005594&newsLang=en 20080522005594en Wed, 21 May 2008 20:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080521006200&newsLang=en 20080521006200en Tue, 20 May 2008 16:00:00 UT SAN FRANCISCO--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. and Pfizer Inc. (NYSE:PFE) today announced the initiation of a worldwide collaborative research and license agreement. The http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080520006164&newsLang=en 20080520006164en Fri, 16 May 2008 14:05:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that study results across several difficult-to-treat cancers will be presented at the 44th American Society of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080516005490&newsLang=en 20080516005490en Thu, 15 May 2008 16:04:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc Chief Financial Officer, Frank D http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080515005970&newsLang=en 20080515005970en Wed, 14 May 2008 22:12:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named Garry A. Nicholson as Senior Vice President, General Manager of the company’s newly created Oncology http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080514006560&newsLang=en 20080514006560en Wed, 14 May 2008 19:41:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has posted a list of U.S. medical, scientific and patient organization grants and charitable contributions made in the first quarter http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080514006375&newsLang=en 20080514006375en Tue, 13 May 2008 14:57:00 UT BEIJING, China--(BUSINESS WIRE)--BEIJING, CHINA, MAY 13 – Today Pfizer China announced it is providing up to RMB 10 million (approximately $1.4 million U.S.D) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080513006099&newsLang=en 20080513006099en Thu, 1 May 2008 12:30:00 UT ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--Esperion Therapeutics, Inc. a biopharmaceutical company formed to focus on the discovery and development of compounds to treat cardiovascular http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080501005628&newsLang=en 20080501005628en Wed, 30 Apr 2008 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080430005619&newsLang=en 20080430005619en Mon, 28 Apr 2008 19:23:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer, Jeffrey http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080428006483&newsLang=en 20080428006483en Fri, 25 Apr 2008 19:06:00 UT SANTA BARBARA, Calif.--(BUSINESS WIRE)--Pfizer has entered into a collaboration agreement with four major research universities – University of California, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080425005715&newsLang=en 20080425005715en Thu, 24 Apr 2008 18:00:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent second–quarter, 2008, dividend on the company http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080424006238&newsLang=en 20080424006238en Thu, 24 Apr 2008 14:30:00 UT MEMPHIS, Tenn.--(BUSINESS WIRE)--Today at Pfizer’s annual shareholder meeting, Chairman and Chief Executive Officer Jeffrey B. Kindler detailed his plan to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080424005852&newsLang=en 20080424005852en Wed, 23 Apr 2008 21:00:00 UT PARIS--(BUSINESS WIRE)--Pfizer Animal Health today announced that it has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation covering all major http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080423006272&newsLang=en 20080423006272en Tue, 22 Apr 2008 04:45:00 UT TOKYO--(BUSINESS WIRE)--Pfizer Inc announced today that on May 8, 2008, it will launch Champix® Tablet 0.5mg/1mg (varenicline tartrate), a novel smoking cessation aid http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080421006554&newsLang=en 20080421006554en Mon, 21 Apr 2008 18:17:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Central Daylight Time) on Thursday, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080421006246&newsLang=en 20080421006246en Mon, 21 Apr 2008 14:52:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Lipitor® (atorvastatin calcium) 80 mg reduced the risk of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080421005882&newsLang=en 20080421005882en Mon, 21 Apr 2008 14:30:00 UT TOKYO--(BUSINESS WIRE)--Pfizer Japan Inc announced that on April 16, the company received an approval for the manufacturing and marketing authorization of the anti-tumor drug/kinase http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080421005854&newsLang=en 20080421005854en Fri, 18 Apr 2008 14:36:00 UT BRUSSELS, Belgium--(BUSINESS WIRE)--A new development centre for veterinary vaccines which will accelerate the development of new animal health products has been opened by Pfizer as part of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080418005449&newsLang=en 20080418005449en Thu, 17 Apr 2008 20:24:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080417006299&newsLang=en 20080417006299en Thu, 17 Apr 2008 11:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080417005548&newsLang=en 20080417005548en Wed, 16 Apr 2008 23:33:00 UT NEW YORK--(BUSINESS WIRE)--In a study in patients with mild-to-moderate Alzheimer’s disease (AD), the addition of Lipitor (atorvastatin calcium tablets) 80 mg http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080416006472&newsLang=en 20080416006472en Wed, 16 Apr 2008 20:37:00 UT NEW YORK & NEEDHAM, Mass.--(BUSINESS WIRE)--Pfizer, Inc (NYSE: PFE) and AVANT Immunotherapeutics (Nasdaq: AVAN), acting through its wholly-owned subsidiary Celldex Therapeutics, Inc. today http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080416006348&newsLang=en 20080416006348en Wed, 16 Apr 2008 12:00:00 UT CHICAGO--(BUSINESS WIRE)--Pfizer’s Lyrica reduced pain of fibromyalgia in patients regardless of whether they experienced symptoms of anxiety or depression at http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080416005388&newsLang=en 20080416005388en Tue, 15 Apr 2008 12:15:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the subsequent offering period of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080415005848&newsLang=en 20080415005848en Wed, 9 Apr 2008 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it updated the US product labeling for EXUBERA® (insulin human [rDNA original http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080409005647&newsLang=en 20080409005647en Tue, 8 Apr 2008 12:10:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has extended the subsequent offering period of its http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080408005760&newsLang=en 20080408005760en Mon, 7 Apr 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--On April 1, 2008, Pfizer Inc (NYSE: PFE) announced results of its tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080407005715&newsLang=en 20080407005715en Tue, 1 Apr 2008 21:48:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Phase III clinical trial (A3671009), of single-agent tremelimumab (CP-675,206) in patients with advanced http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080401006838&newsLang=en 20080401006838en Tue, 1 Apr 2008 16:18:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) 80 mg showed unexpectedly potent reduction in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080401006350&newsLang=en 20080401006350en Tue, 1 Apr 2008 14:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10am EDT on Thursday, April http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080401006103&newsLang=en 20080401006103en Tue, 1 Apr 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has purchased all of the shares validly tendered and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080401005980&newsLang=en 20080401005980en Mon, 31 Mar 2008 17:02:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080331006194&newsLang=en 20080331006194en Thu, 27 Mar 2008 21:05:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that it has obtained clearance from the Federal Cartel Office of Germany (FCO) in connection with the tender offer by its http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080327006161&newsLang=en 20080327006161en Thu, 27 Mar 2008 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired in connection http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080327005304&newsLang=en 20080327005304en Thu, 20 Mar 2008 23:27:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Federal Court of Appeal of Canada has reversed a lower court ruling that held that Pfizer’s http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080320006108&newsLang=en 20080320006108en Tue, 18 Mar 2008 21:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health today announced it will acquire two market-leading livestock genomics companies: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080318005479&newsLang=en 20080318005479en Wed, 12 Mar 2008 15:43:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080312005896&newsLang=en 20080312005896en Tue, 11 Mar 2008 20:16:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said today that Senior Vice President and General Counsel Allen Waxman is leaving the company for personal reasons. Mr. Waxman will remain outside counsel http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080311006490&newsLang=en 20080311006490en Mon, 10 Mar 2008 18:17:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chief Medical Officer, Joseph Feczko, at the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080310006227&newsLang=en 20080310006227en Fri, 7 Mar 2008 18:34:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080307005571&newsLang=en 20080307005571en Wed, 5 Mar 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today reviewed strategies to accelerate and refocus Pfizer’s pipeline and capture new opportunities for global growth at a http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080305005604&newsLang=en 20080305005604en Tue, 4 Mar 2008 21:56:00 UT NEW YORK & HOUSTON--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced the commencement of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., for all http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080304006506&newsLang=en 20080304006506en Mon, 3 Mar 2008 15:10:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named William Ringo as the company’s new Senior Vice President of Strategy and Business Development with http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080303005856&newsLang=en 20080303005856en Mon, 3 Mar 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire Serenex, Inc., a privately-held biotechnology company with a Phase I clinical candidate http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080303005673&newsLang=en 20080303005673en Thu, 28 Feb 2008 15:11:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it will seek to appeal a ruling of the Court of Appeal of The Hague in the Netherlands that Pfizer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080228005655&newsLang=en 20080228005655en Mon, 25 Feb 2008 19:21:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said today that it is voluntarily withdrawing Lipitor advertising and promotion featuring Dr. Robert Jarvik and committing to ensuring greater clarity in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080225006247&newsLang=en 20080225006247en Thu, 21 Feb 2008 13:42:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin - the active ingredient in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080221005525&newsLang=en 20080221005525en Wed, 20 Feb 2008 14:14:00 UT NEW YORK & HOUSTON--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire Encysive Pharmaceuticals Inc. (NASDAQ: ENCY), a publicly held http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080220005732&newsLang=en 20080220005732en Tue, 19 Feb 2008 17:00:00 UT NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation announced today a groundbreaking $33 million multi-year program to address the emerging challenges in cancer and tobacco control. The first http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080219006226&newsLang=en 20080219006226en Wed, 13 Feb 2008 06:00:00 UT JOHANNESBURG, South Africa--(BUSINESS WIRE)--An international conference to discuss the issue of counterfeit medicines in Africa started this week in Johannesburg. The aim of the conference, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080212006465&newsLang=en 20080212006465en Wed, 6 Feb 2008 23:00:00 UT BOSTON--(BUSINESS WIRE)--At this week’s major HIV/AIDS research meeting, Pfizer presented new data on two investigational second generation HIV compounds http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080206006429&newsLang=en 20080206006429en Tue, 29 Jan 2008 01:10:00 UT TOKYO--(BUSINESS WIRE)--Pfizer Japan Inc (headquarter in Shibuya-ku, Tokyo; headed by President & Chief Executive Officer, Hiromitsu Iwasaki; and capitalized at Yen 64.8 billion) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080128006401&newsLang=en 20080128006401en Wed, 23 Jan 2008 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080123005596&newsLang=en 20080123005596en Tue, 22 Jan 2008 11:00:00 UT NEW YORK--(BUSINESS WIRE)--As millions of Americans vow to get healthier and stave off illness by making a New Year’s resolution to lose weight, it http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080122005096&newsLang=en 20080122005096en Fri, 18 Jan 2008 16:25:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on Wednesday, March 5, at http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080118005487&newsLang=en 20080118005487en Fri, 18 Jan 2008 13:30:00 UT NEW YORK--(BUSINESS WIRE)--Cigarette smoking is associated with significant morbidity and mortality. Smoking is the leading preventable cause of disease and premature death in the United http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080118005312&newsLang=en 20080118005312en Wed, 16 Jan 2008 17:04:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the eighth class of Global Health Fellows, a group of 28 Pfizer colleagues from North America, Europe and Asia, who http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080116005853&newsLang=en 20080116005853en Wed, 16 Jan 2008 16:38:00 UT NEW YORK--(BUSINESS WIRE)--The early addition of Lipitor® (atorvastatin calcium) Tablets to effective blood pressure lowering http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080116005815&newsLang=en 20080116005815en Wed, 16 Jan 2008 09:00:00 UT NEW YORK & MARTINSRIED, Germany--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080116005149&newsLang=en 20080116005149en Tue, 15 Jan 2008 14:00:00 UT NEW YORK--(BUSINESS WIRE)--European vets are about to be given the same powerful medical tool which has helped U.S. vets manage obese dogs who don’t respond http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080115005237&newsLang=en 20080115005237en Mon, 14 Jan 2008 15:40:00 UT NEW YORK--(BUSINESS WIRE)--Results of an observational study of a large U.S. managed care claims database showed that new statin users without cardiovascular disease who http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080114005957&newsLang=en 20080114005957en Mon, 14 Jan 2008 12:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the ‘893 http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080114005471&newsLang=en 20080114005471en Wed, 9 Jan 2008 23:23:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a New York state court ruled in favor of the company on an important motion relating to litigation over Pfizer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080109006168&newsLang=en 20080109006168en Wed, 9 Jan 2008 19:44:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EST on Wednesday, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080109005951&newsLang=en 20080109005951en Tue, 8 Jan 2008 17:25:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named Sally Susman Senior Vice President of Worldwide Communications and Chief Communications Officer with overall responsibility for Pfizer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080108005866&newsLang=en 20080108005866en Mon, 7 Jan 2008 06:00:00 UT NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc [Headquarter: New York, NY, USA, CEO: Jeffrey B. Kindler] (hereinafter, Pfizer) and Taisho http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080106005057&newsLang=en 20080106005057en Thu, 3 Jan 2008 17:15:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today it will appeal a Canadian Federal Court decision in favor of generic manufacturer Apotex in its challenge to a Pfizer patent covering http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080103005803&newsLang=en 20080103005803en Thu, 3 Jan 2008 12:14:00 UT LONDON--(BUSINESS WIRE)--84 percent of ex-smokers who consulted with their doctor or another healthcare professional during their final successful quit attempt believe that giving up would http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20080103005463&newsLang=en 20080103005463en Mon, 31 Dec 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that it has completed the cash tender offer to purchase all of the outstanding shares of common stock of Coley Pharmaceutical http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071231005125&newsLang=en 20071231005125en Fri, 21 Dec 2007 19:05:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) issued for dalbavancin HCl, Pfizer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071221005672&newsLang=en 20071221005672en Fri, 21 Dec 2007 15:13:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc recently conducted a comparative analysis of the tropism assays TrofileTM, provided by Monogram Biosciences, and SensiTrop http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071221005433&newsLang=en 20071221005433en Tue, 18 Dec 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired, and that it has http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071218005121&newsLang=en 20071218005121en Tue, 18 Dec 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071218005293&newsLang=en 20071218005293en Mon, 17 Dec 2007 20:26:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent first–quarter, 2008, dividend on the company http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071217006026&newsLang=en 20071217006026en Wed, 5 Dec 2007 12:00:00 UT NEW YORK & EXTON, Pa.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Adolor Corporation (Nasdaq: ADLR) announced today an exclusive worldwide collaboration to develop and commercialize novel http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071205005309&newsLang=en 20071205005309en Fri, 30 Nov 2007 13:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced the commencement of its cash tender offer for all outstanding shares of common stock of Coley Pharmaceutical Group, Inc. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071130005252&newsLang=en 20071130005252en Fri, 16 Nov 2007 18:22:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Friday, November 30, at http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071116005580&newsLang=en 20071116005580en Fri, 16 Nov 2007 13:31:00 UT NEW YORK & WELLESLEY, Mass.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY), a http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071116005284&newsLang=en 20071116005284en Tue, 13 Nov 2007 13:30:00 UT NEW YORK & SAN CARLOS, Calif.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Nektar Therapeutics (NASDAQ: NKTR) announced today that the two companies have resolved all outstanding contractual http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071113005860&newsLang=en 20071113005860en Tue, 6 Nov 2007 16:30:00 UT ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) was more effective than http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071106006080&newsLang=en 20071106006080en Mon, 5 Nov 2007 14:30:00 UT ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today that post-stroke or mini-stroke patients treated with Lipitor® (atorvastatin http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071105006007&newsLang=en 20071105006007en Sun, 4 Nov 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the cardiovascular and kidney function effects of Lipitor® (atorvastatin calcium) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071104005039&newsLang=en 20071104005039en Tue, 30 Oct 2007 07:00:00 UT TOKYO & NEW YORK--(BUSINESS WIRE)--Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara] http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071030005478&newsLang=en 20071030005478en Mon, 29 Oct 2007 19:17:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company’s patent covering atorvastatin http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071029006376&newsLang=en 20071029006376en Thu, 25 Oct 2007 20:45:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said today that after a 31-year career Vice Chairman David L. Shedlarz will retire from the company at the end of this year. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071025006342&newsLang=en 20071025006342en Thu, 25 Oct 2007 17:00:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent fourth-quarter, 2007, dividend on the company's common stock, payable December 4, 2007, to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071025005940&newsLang=en 20071025005940en Tue, 23 Oct 2007 13:51:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071023006031&newsLang=en 20071023006031en Thu, 18 Oct 2007 10:30:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071018005482&newsLang=en 20071018005482en Mon, 15 Oct 2007 04:01:00 UT NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc (www.pfizer.com) and Sermo ( http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071014005075&newsLang=en 20071014005075en Thu, 11 Oct 2007 15:00:00 UT WASHINGTON--(BUSINESS WIRE)--The Brookings Institution’s Initiative on International Volunteering and Service, FSG Social Impact Advisors and Pfizer Inc, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071011005169&newsLang=en 20071011005169en Fri, 5 Oct 2007 15:06:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Thursday, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071005005406&newsLang=en 20071005005406en Thu, 4 Oct 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today named Dr. Martin Mackay as President of Pfizer Global Research and Development (PGRD); launched an independent, stand-alone biotherapeutics and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071004005573&newsLang=en 20071004005573en Wed, 3 Oct 2007 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that Dr. Tanya Clemons, a senior executive with extensive experience in leadership and organization change at Microsoft and IBM, will join http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20071003005361&newsLang=en 20071003005361en Fri, 28 Sep 2007 16:32:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s second medical use patent covering Viagra http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070928005588&newsLang=en 20070928005588en Fri, 28 Sep 2007 15:59:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that in recognition for its approach to improving the environment, the company was named to the Climate Disclosure Leadership Index http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070928005559&newsLang=en 20070928005559en Thu, 27 Sep 2007 16:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the election of Suzanne Nora Johnson and James M. Kilts to the Pfizer Board of Directors effective September 27, 2007. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070927005712&newsLang=en 20070927005712en Wed, 26 Sep 2007 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Preliminary results from a new Phase II study provide data on the anti-tumor activity and tolerability of sunitinib malate in patients with http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070926005600&newsLang=en 20070926005600en Mon, 24 Sep 2007 07:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the European Commission (EC) has approved Celsentri® (maraviroc). http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070924005148&newsLang=en 20070924005148en Fri, 21 Sep 2007 18:08:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that an appeals court has overturned a lower court ruling that several generic manufacturers did not infringe the company http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070921005519&newsLang=en 20070921005519en Fri, 21 Sep 2007 07:00:00 UT AMSTERDAM, Netherlands--(BUSINESS WIRE)--Pfizer and the European Foundation for the Study of Diabetes (EFSD) announced today, at the European Association for the Study of Diabetes (EASD) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070921005134&newsLang=en 20070921005134en Wed, 19 Sep 2007 16:46:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, Vice President, Pfizer Global Research http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070919006128&newsLang=en 20070919006128en Tue, 18 Sep 2007 15:00:00 UT CHICAGO--(BUSINESS WIRE)--Nearly three times as many patients receiving Selzentry, in addition to an optimized background regimen, achieved undetectable levels of HIV virus compared with http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070918006086&newsLang=en 20070918006086en Tue, 18 Sep 2007 07:00:00 UT AMSTERDAM, Netherlands--(BUSINESS WIRE)--Two new studies presented today at the European Association for the Study of Diabetes (EASD) meeting reinforce the efficacy and safety of Exubera http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070918005216&newsLang=en 20070918005216en Thu, 13 Sep 2007 19:38:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, Senior Vice President, Pfizer Inc., President, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070913005929&newsLang=en 20070913005929en Thu, 13 Sep 2007 15:44:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the company plans to present key data on in-line medicines and pipeline research at the Annual Meeting of Interscience Conference on http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070913005689&newsLang=en 20070913005689en Wed, 12 Sep 2007 21:02:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s patent covering a crystalline form of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070912006331&newsLang=en 20070912006331en Thu, 6 Sep 2007 03:30:00 UT SEOUL, Korea--(BUSINESS WIRE)--Pfizer announced today the initiation of a large, global Phase III clinical trial to evaluate the efficacy and safety of sunitinib malate, in combination with http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070905006587&newsLang=en 20070905006587en Wed, 5 Sep 2007 15:28:00 UT NAIROBI--(BUSINESS WIRE)--To help address critical gaps in malaria treatment and education, Pfizer today announced the launch of Mobilize Against Malaria. This three-country http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070905005950&newsLang=en 20070905005950en Wed, 5 Sep 2007 15:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer Jeffrey http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070905005903&newsLang=en 20070905005903en Wed, 5 Sep 2007 06:03:00 UT VIENNA, Austria--(BUSINESS WIRE)--An observational study of a large United Kingdom primary care database showed that switching patients from Pfizer’s http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070904006477&newsLang=en 20070904006477en Mon, 27 Aug 2007 11:30:00 UT NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Bristol-Myers Squibb Company (NYSE:BMY) (“companies”) today http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070827005440&newsLang=en 20070827005440en Wed, 22 Aug 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced that Frank A. D’Amelio, a senior executive with almost three decades of extensive operating and financial http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070822005442&newsLang=en 20070822005442en Mon, 6 Aug 2007 20:33:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said today that it now has a total of 47 programs in its Phase II Research and Development pipeline, which is the largest Phase II cohort in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070808005625&newsLang=en 20070808005625en Mon, 6 Aug 2007 17:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved SelzentryTM (maraviroc) tablets, the first in a http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070806005899&newsLang=en 20070806005899en Thu, 2 Aug 2007 23:01:00 UT PARIS--(BUSINESS WIRE)--Guidelines from the 2007 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, published today in the Annals of Oncology ( http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070802005927&newsLang=en 20070802005927en Mon, 30 Jul 2007 16:01:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health, a business of Pfizer Inc (NYSE: PFE), announced today that Cerenia™ (maropitant http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070730005825&newsLang=en 20070730005825en Wed, 25 Jul 2007 11:04:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a Spanish court has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070725005484&newsLang=en 20070725005484en Wed, 25 Jul 2007 04:01:00 UT NEW YORK--(BUSINESS WIRE)--Rates of virologic suppression in patients receiving Pfizer’s novel CCR5 antagonist, maraviroc, compared to efavirenz (EFV) were 70.6% http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070724006462&newsLang=en 20070724006462en Thu, 19 Jul 2007 21:26:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070719006109&newsLang=en 20070719006109en Wed, 18 Jul 2007 18:34:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced its first occupant for the company’s Incubator – a new http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070718005922&newsLang=en 20070718005922en Wed, 18 Jul 2007 10:45:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070718005442&newsLang=en 20070718005442en Tue, 10 Jul 2007 10:45:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070710005680&newsLang=en 20070710005680en Mon, 9 Jul 2007 16:44:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has been notified of an unsolicited “mini-tender offer” by TRC Capital Corporation http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070709006012&newsLang=en 20070709006012en Tue, 3 Jul 2007 17:50:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Wednesday, July 18. The http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070703005635&newsLang=en 20070703005635en Sat, 30 Jun 2007 09:00:00 UT BARCELONA--(BUSINESS WIRE)--Data presented for the first time in Europe reinforce the position of irinotecan as a key component of first line therapy in the management of patients with http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070630005002&newsLang=en 20070630005002en Thu, 28 Jun 2007 13:18:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer today declared a 29-cent third-quarter, 2007, dividend on the company's common stock, payable September 5, 2007, to shareholders http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070628005572&newsLang=en 20070628005572en Thu, 28 Jun 2007 13:10:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said today that members of its Board of Directors will invite its largest institutional shareholders to a meeting where they will have an opportunity to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070628005559&newsLang=en 20070628005559en Thu, 28 Jun 2007 07:00:00 UT BARCELONA, Spain--(BUSINESS WIRE)--Pfizer announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of sunitinib malate, in combination with a standard http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070628005202&newsLang=en 20070628005202en Mon, 25 Jun 2007 14:06:00 UT CHICAGO--(BUSINESS WIRE)--Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070625005736&newsLang=en 20070625005736en Sat, 23 Jun 2007 15:00:00 UT CHICAGO--(BUSINESS WIRE)--Results from three-year interim analyses of two ongoing long-term clinical trials showed that small mean declines in lung function in diabetes patients who took http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070623005012&newsLang=en 20070623005012en Thu, 21 Jun 2007 20:03:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the Food and Drug Administration (FDA) approved Lyrica® (pregabalin) capsules http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070621005991&newsLang=en 20070621005991en Wed, 20 Jun 2007 21:33:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today the U.S. Food and Drug Administration (FDA) issued an approvable letter for maraviroc, which is under review as a therapy for http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070620006242&newsLang=en 20070620006242en Wed, 20 Jun 2007 17:50:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today the discontinuation of a development program in lung cancer for PF-3512676, an investigational compound, in combination with http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070620006009&newsLang=en 20070620006009en Tue, 12 Jun 2007 13:09:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health (NYSE: PFE) today announced that SLENTROL™ (dirlotapide), the first http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070612005727&newsLang=en 20070612005727en Thu, 7 Jun 2007 19:14:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, Senior Vice President of Pfizer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070607005873&newsLang=en 20070607005873en Tue, 5 Jun 2007 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts yesterday in connection with the American http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070605005297&newsLang=en 20070605005297en Mon, 4 Jun 2007 13:05:00 UT CHICAGO--(BUSINESS WIRE)--Pfizer announced today that axitinib (AG-013736), an investigational oral, selective inhibitor of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070604005791&newsLang=en 20070604005791en Sun, 3 Jun 2007 19:00:00 UT CHICAGO--(BUSINESS WIRE)--Pfizer announced today that single-agent, oral SUTENT® (sunitinib malate) prolonged progression-free survival (PFS) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070603005057&newsLang=en 20070603005057en Sun, 3 Jun 2007 12:30:00 UT CHICAGO--(BUSINESS WIRE)--Data on Pfizer’s investigational compound CP-675,206, which works by a novel mechanism of action and represents a new http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070605006049&newsLang=en 20070605006049en Sat, 2 Jun 2007 22:00:00 UT CHICAGO--(BUSINESS WIRE)--Pfizer said today that clinical trials examining its different cancer-fighting approaches showed activity in patients with non-small cell lung cancer (NSCLC). Data http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070602005029&newsLang=en 20070602005029en Wed, 30 May 2007 13:04:00 UT ST. LOUIS & NEW YORK--(BUSINESS WIRE)--Express Scripts, Inc. (NASDAQ: ESRX), and Pfizer Inc (NYSE: PFE), today announced an agreement providing for Pfizer’s http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070530005673&newsLang=en 20070530005673en Wed, 30 May 2007 08:47:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has recommended Champix (varenicline) for http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070530005488&newsLang=en 20070530005488en Tue, 29 May 2007 15:42:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Monday, June 4, at 6:00 http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070529005837&newsLang=en 20070529005837en Tue, 29 May 2007 15:41:00 UT --(BUSINESS WIRE)--At next week’s American Society of Clinical Oncology Meeting, Pfizer will present new information that underscores the depth and breadth of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070529005834&newsLang=en 20070529005834en Tue, 29 May 2007 15:39:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said today that results showing potential across numerous types of cancer, such as melanoma, thyroid, liver, non-small cell lung (NSCLC), colorectal (CRC) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070529005833&newsLang=en 20070529005833en Tue, 29 May 2007 14:19:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc. said today that it will immediately seek to appeal a ruling by the Borgarting Court of Appeal in Oslo, Norway that four of Pfizer http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070529005741&newsLang=en 20070529005741en Sun, 27 May 2007 02:11:00 UT RIO VISTA, Calif.--(BUSINESS WIRE)--Responding to a request from the Marine Mammal Center, Pfizer Animal Health (PAH) has donated an antibiotic which was used today to treat the two humpback http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070526005012&newsLang=en 20070526005012en Thu, 24 May 2007 08:00:00 UT BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) (LSE:PFZ) welcomes the European Commission’s Green Paper on smoke free environments http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070524005315&newsLang=en 20070524005315en Mon, 21 May 2007 01:25:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070520005047&newsLang=en 20070520005047en Tue, 15 May 2007 23:06:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said its subsidiary, Pharmacia and Upjohn, will appeal today’s jury verdict linking its product, Provera, with plaintiff Merle http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070515006646&newsLang=en 20070515006646en Mon, 14 May 2007 10:27:00 UT BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer welcomes the 1st European Parliamentary symposium on pharmaceuticals “Putting an end to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070514005570&newsLang=en 20070514005570en Wed, 2 May 2007 13:35:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has launched an online site to provide up-to-date, user-friendly information on the status of its U.S. post-marketing commitments. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070502005726&newsLang=en 20070502005726en Tue, 1 May 2007 20:15:00 UT BOSTON--(BUSINESS WIRE)--Significantly more patients treated with Pfizer’s Lyrica reduced their pain by 50 percent or more compared with placebo, according to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070501006565&newsLang=en 20070501006565en Mon, 30 Apr 2007 20:24:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc reported today that the Federal Court of Appeal of Canada has reversed a lower court ruling that would have permitted generic manufacturer Novopharm to http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070430006349&newsLang=en 20070430006349en Mon, 30 Apr 2007 10:00:00 UT NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation today announced the names of 20 U.S. community-based AIDS service organizations (ASOs) chosen to participate in ConnectHIV, the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070430005154&newsLang=en 20070430005154en Fri, 27 Apr 2007 16:32:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Vice Chairman David Shedlarz at the 32nd http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070427005544&newsLang=en 20070427005544en Thu, 26 Apr 2007 15:00:00 UT NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent second-quarter, 2007, dividend on the company's common stock, payable June 5, 2007, to shareholders http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070426005819&newsLang=en 20070426005819en Thu, 26 Apr 2007 14:48:00 UT SOUTH BEND, Ind.--(BUSINESS WIRE)--In remarks at the annual shareholders meeting, Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler said, “We http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070426005803&newsLang=en 20070426005803en Thu, 26 Apr 2007 11:00:00 UT PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) today announced a worldwide collaboration to develop and commercialize http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070426005515&newsLang=en 20070426005515en Tue, 24 Apr 2007 21:43:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted unanimously (12-0) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070424006547&newsLang=en 20070424006547en Fri, 20 Apr 2007 10:43:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070420005230&newsLang=en 20070420005230en Thu, 19 Apr 2007 19:41:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070419006073&newsLang=en 20070419006073en Mon, 9 Apr 2007 13:58:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Friday, April 20. The http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070409005507&newsLang=en 20070409005507en Mon, 2 Apr 2007 17:38:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that two subsidiaries of Pharmacia have reached separate settlements with the United States Department of Justice to address charges http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070402006143&newsLang=en 20070402006143en Tue, 27 Mar 2007 17:20:00 UT NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070327006171&newsLang=en 20070327006171en Mon, 26 Mar 2007 20:30:00 UT NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070326006206&newsLang=en 20070326006206en Mon, 26 Mar 2007 15:27:00 UT NEW ORLEANS--(BUSINESS WIRE)--Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070326005917&newsLang=en 20070326005917en Fri, 23 Mar 2007 21:01:00 UT NEW YORK--(BUSINESS WIRE)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070323005696&newsLang=en 20070323005696en Fri, 23 Mar 2007 14:14:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the effect of Lipitor (atorvastatin calcium) on atherosclerosis, cardiovascular events such as heart attacks and http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070323005408&newsLang=en 20070323005408en Thu, 22 Mar 2007 17:59:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070322005917&newsLang=en 20070322005917en Wed, 21 Mar 2007 15:00:00 UT NEW YORK--(BUSINESS WIRE)--In response to recent news coverage of Exubera, Pfizer believes people with diabetes and their families should have the following information http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070425005908&newsLang=en 20070425005908en Tue, 20 Mar 2007 19:36:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a federal court in the District of New Jersey (Newark) has upheld the three main U.S. patents covering Celebrex, the company http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070320006295&newsLang=en 20070320006295en Tue, 20 Mar 2007 18:40:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the Women’s Business Enterprise National Council (WBENC), the nation http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070320006250&newsLang=en 20070320006250en Mon, 12 Mar 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) invites investors and the general public to view and listen to webcasts of presentations by Vice Chairman David Shedlarz at http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070314005520&newsLang=en 20070314005520en Wed, 7 Mar 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Lipitor® (atorvastatin calcium) http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070314005507&newsLang=en 20070314005507en Fri, 2 Mar 2007 13:00:00 UT BUENA VISTA, Fla.--(BUSINESS WIRE)--A retrospective analysis of a large U.S. managed care database showed that patients who took Pfizer's cholesterol-lowering medicine http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070314005496&newsLang=en 20070314005496en Thu, 1 Mar 2007 13:00:00 UT LOS ANGELES--(BUSINESS WIRE)--At this week's major HIV/AIDS research meeting, Pfizer presented pivotal data of its experimental medicine, maraviroc, which tackles HIV in an http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070314005489&newsLang=en 20070314005489en Tue, 27 Feb 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a federal court in the Western District of Pennsylvania (Pittsburgh) has upheld the company's U.S. patent covering the http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070314005471&newsLang=en 20070314005471en Fri, 23 Feb 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer said today that Constance J. Horner, a member of the company's Board of Directors since 1993, has been elected lead director effective http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070314005464&newsLang=en 20070314005464en Fri, 23 Feb 2007 13:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070314005457&newsLang=en 20070314005457en Tue, 13 Feb 2007 13:14:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005493&newsLang=en 20070222005493en Thu, 8 Feb 2007 13:23:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) has approved new labeling of Sutent® http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005509&newsLang=en 20070222005509en Wed, 7 Feb 2007 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Patients with coronary heart disease who took Lipitor® (atorvastatin calcium) 80 mg tablets reduced their risk of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070314005895&newsLang=en 20070314005895en Thu, 1 Feb 2007 13:47:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire BioRexis Pharmaceutical Corporation, a privately-held http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005539&newsLang=en 20070222005539en Wed, 31 Jan 2007 14:07:00 UT NEW YORK--(BUSINESS WIRE)--The federal district court in the Eastern District of Virginia (Alexandria) has ruled that Synthon IP obtained, by inequitable conduct, two http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005554&newsLang=en 20070222005554en Thu, 25 Jan 2007 14:18:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it will appeal a decision by the Canadian Federal Court in Toronto denying its application to block approval of http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005566&newsLang=en 20070222005566en Mon, 22 Jan 2007 16:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005780&newsLang=en 20070222005780en Mon, 22 Jan 2007 14:54:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler today announced the company's immediate priorities to drive improved http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005606&newsLang=en 20070222005606en Fri, 19 Jan 2007 15:07:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health, a division of Pfizer Inc (NYSE: PFE) today announced the completion of its acquisition of Embrex, Inc. (NASDAQ: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005615&newsLang=en 20070222005615en Thu, 18 Jan 2007 15:15:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that Sutent® (sunitinib malate) has received the European Commission’s http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005624&newsLang=en 20070222005624en Tue, 16 Jan 2007 12:00:00 UT NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1017152&newsId=20070222005640&newsLang=en 20070222005640en